EuBiologics' RSV 피망 바카라 candidate EuRSV shows safety in interim Phase 1 trial results

[by Sung, Jae Jun] EuBiologics announced on September 24 that it has obtained the interim results report from its ongoing domestic Phase 1 clinical trial of its respiratory syncytial virus (RSV) 피망 바카라 candidate, EuRSV.

The study, conducted at Korea University Guro Hospital, enrolled 100 healthy adults between the ages of 19 and 80. Participants were randomly assigned to low- and high-dose cohorts of the RSV-1 and RSV-2 피망 바카라 candidates, with the trial designed as placebo-controlled and observer-blinded.

According to the interim results, neither 피망 바카라 candidate was associated with any serious adverse drug reactions (SADRs). Reported side effects, including pain, tenderness, fatigue, and headache, were limited to the anticipated mild to moderate range and resolved without complications.

Building on these results, EuBiologics plans to determine the final formulation and dosage of its lead 피망 바카라 candidate. In partnership with its U.S. subsidiary, EuPoP Life Sciences (EuPoP LS), the company will also shape a differentiated market entry strategy covering the Korean market, the public 피망 바카라 sector, and advanced global markets. The company expected to release the final clinical study report (CSR) for the Phase 1 clinical trial by the end of the second quarter of 2026.

"The confirmation of safety of our second RSV 피망 바카라 candidate through a domestic clinical trial, leveraging our proprietary 피망 바카라 platform, establishes a strategic foundation for advancing into the global premium 피망 바카라 market," an EuBiologics official said.